Department of Analysis, Universidade Federal do Rio Grande do Sul (UFRGS), School of Pharmacy, Porto Alegre, RS, Brazil
Search for other papers by Simone Martins de Castro in
Google Scholar
PubMed
Search for other papers by Paloma Wiest in
Google Scholar
PubMed
Search for other papers by Poli Mara Spritzer in
Google Scholar
PubMed
Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil
Department of Pediatrics, Universidade Federal do Rio Grande do Sul (UFRGS), Medical School, Porto Alegre, RS, Brazil
Search for other papers by Cristiane Kopacek in
Google Scholar
PubMed
classical CAH ranges from 1:7500 to 1:18,000 live births ( 12 ). However, the incidence varies from state to state ( 13 , 14 , 15 , 16 ). Screening for CAH aims to identify newborns most likely to be affected by the more severe forms of the disease
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER, Unidad 747), ISCIII, Spain
Department of Endocrinology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Search for other papers by Susan M Webb in
Google Scholar
PubMed
Search for other papers by Jette Kristensen in
Google Scholar
PubMed
Search for other papers by Anna Nordenström in
Google Scholar
PubMed
Search for other papers by Diana Vitali in
Google Scholar
PubMed
Search for other papers by Vincent Amodru in
Google Scholar
PubMed
Search for other papers by Lenja Katharina Wiehe in
Google Scholar
PubMed
Search for other papers by Matt Bolz-Johnson in
Google Scholar
PubMed
, while the newborn and father were taken to the neonatal ICU facilities. A boy identified via neonatal screening was reported by the parents. Symptoms of irritability and insufficient weight gain did not give the diagnosis before the screening result at
Search for other papers by Paul-Martin Holterhus in
Google Scholar
PubMed
Search for other papers by Alexandra Kulle in
Google Scholar
PubMed
Search for other papers by Anne-Marie Till in
Google Scholar
PubMed
Search for other papers by Caroline Stille in
Google Scholar
PubMed
Search for other papers by Tabea Lamprecht in
Google Scholar
PubMed
Search for other papers by Simon Vieth in
Google Scholar
PubMed
Search for other papers by Melchior Lauten in
Google Scholar
PubMed
://doi.org/10.1111/j.1365-2265.2006.02740.x ) 11 Peter M Janzen N Sander S Korsch E Riepe FG & Sander J . A case of 11beta-hydroxylase deficiency detected in a newborn screening program by second-tier LC-MS/MS . Hormone Research 2008 69 253
Search for other papers by Avinaash Maharaj in
Google Scholar
PubMed
Search for other papers by Ruth Kwong in
Google Scholar
PubMed
Search for other papers by Jack Williams in
Google Scholar
PubMed
Search for other papers by Christopher Smith in
Google Scholar
PubMed
Search for other papers by Helen Storr in
Google Scholar
PubMed
Search for other papers by Ruth Krone in
Google Scholar
PubMed
Search for other papers by Debora Braslavsky in
Google Scholar
PubMed
Search for other papers by Maria Clemente in
Google Scholar
PubMed
Search for other papers by Nanik Ram in
Google Scholar
PubMed
Search for other papers by Indraneel Banerjee in
Google Scholar
PubMed
Search for other papers by Semra Çetinkaya in
Google Scholar
PubMed
Search for other papers by Federica Buonocore in
Google Scholar
PubMed
Search for other papers by Tülay Güran in
Google Scholar
PubMed
Search for other papers by John C Achermann in
Google Scholar
PubMed
Search for other papers by Louise Metherell in
Google Scholar
PubMed
Search for other papers by Rathi Prasad in
Google Scholar
PubMed
, 17 ). Mutations in SGPL1 should therefore be considered as part of the differential diagnosis for PAI of unknown aetiology, in order to initiate early screening and appropriate treatment to reduce morbidity and mortality. This includes careful
Search for other papers by Annelies van’t Westeinde in
Google Scholar
PubMed
Search for other papers by Leif Karlsson in
Google Scholar
PubMed
Search for other papers by Valeria Messina in
Google Scholar
PubMed
Search for other papers by Lena Wallensteen in
Google Scholar
PubMed
Search for other papers by Manuela Brösamle in
Google Scholar
PubMed
Search for other papers by Giorgio Dal Maso in
Google Scholar
PubMed
Search for other papers by Alessandro Lazzerini in
Google Scholar
PubMed
Search for other papers by Jette Kristensen in
Google Scholar
PubMed
Search for other papers by Diana Kwast in
Google Scholar
PubMed
Search for other papers by Lea Tschaidse in
Google Scholar
PubMed
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Hanna F Nowotny in
Google Scholar
PubMed
Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Nicole Reisch in
Google Scholar
PubMed
Search for other papers by Svetlana Lajic in
Google Scholar
PubMed
Introduction Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase (21-OH) deficiency occurs in around 1:10,000–1:15,000 newborns ( 1 , 2 , 3 , 4 , 5 ). It is caused by mutations in the CYP21A2 gene coding for the 21-OH enzyme